BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18834373)

  • 1. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
    Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
    J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
    Huang J; Chuang SK; Cheng CL; Lai ML
    Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
    Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
    Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
    Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
    Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
    Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
    Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
    Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
    Blake CM; Kharasch ED; Schwab M; Nagele P
    Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
    Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
    Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
    Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
    Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
    Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
    Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
    Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
    Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes.
    Bae SH; Lee JK; Cho DY; Bae SK
    J Sep Sci; 2014 Jun; 37(11):1256-64. PubMed ID: 24648255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
    Cho DY; Bae SH; Lee JK; Park JB; Kim YW; Lee S; Oh E; Kim BT; Bae SK
    Xenobiotica; 2015 Mar; 45(3):256-63. PubMed ID: 25268386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
    Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
    Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
    Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
    Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.